CYL 02

Drug Profile

CYL 02

Alternative Names: CYL-02 + gemcitabine

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator InvivoGen Therapeutics
  • Class Gene therapies
  • Mechanism of Action Enzyme induced prodrug activators; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Pancreatic cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, Late-stage disease, Metastatic disease) in France (Intratumoural, Injection)
  • 15 Jun 2016 University Hospital, Toulouse plans a phase II trial for Pancreatic cancer (Combination therapy, Late-stage disease, First-line therapy) in France (NCT02806687)
  • 01 Dec 2010 Phase-I clinical trials in Pancreatic cancer (combination therapy, late-stage disease, metastatic disease) in France (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top